Skeletal resistance to parathyroid hormone as a background abnormality in uremia

Nephrology

Volumn 8, Issue SUPPL., 2003, Pages

  Fukagawa, Masafumi ^a   Iwasaki, Yoshiko ^b   Kazama, Junichiro J ^c  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OITA UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

Bone; Osteoprotegerin; Parathyroid hormone; Uremic toxin; Whole parathyroid hormone

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DISEASE; BONE TURNOVER; CONFERENCE PAPER; CONTROLLED STUDY; DIALYSIS; DOWN REGULATION; HORMONE DETERMINATION; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MOLECULAR DYNAMICS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PARATHYROID FUNCTION; PARATHYROID GLAND; PATHOGENESIS; PRIORITY JOURNAL; RAT; RISK FACTOR; SKELETAL RESISTANCE; SPINE FRACTURE; UREMIA;

ANIMALS; BONE REMODELING; HUMANS; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; UREMIA;

EID: 0348224192     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.8.s.7.x     Document Type: Conference Paper

References (23)

1. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann. Intern. Med. 1973; 78: 357-64.
2. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH. Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure: a possible cause for secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1975; 41: 339-45.
3. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J. Clin. Endocrinol. Metab. 1992; 75: 145-50.
4. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am. J. Kid. Dis. 1995; 26: 622-31.
5. Fukagawa M. Cell biology of parathyroid hyperplasia in uremia. Am. J. Med. Sci. 1999; 317: 377-82.
6. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int. 1993; 43: 436-42.
7. Hercz G, Pei Y, Greenwood C, Manuel A et al. Aplastic osteodystrophy without aluminum: the role of 'suppressed' parathyroid function. Kidney Int. 1993; 44: 860-6.
8. Slatopolsky E, Finch JL, Clay P et al. A novel mechansiam for skeletal resistance in uremia. Kidney Int. 2000; 58: 753-61.
9. Nakanishi S, Kazama JJ, Shigematsu T et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am. J. Kidney Dis. 2001; 38 (Suppl. 1): S172-4.
10. Yamashita H, Gao P, Noguchi S et all. Role of cyclase activating parathyroid hormone (1-84 PTH) measurements during parathyroid surgery: Potential improvement of intraoperative PTH assay. Ann. Surg. 2002; 236: 105-11.
11. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84) /large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001; 60: 1460-8.
12. Ureña P, Ferreria A, Morieux C, Drüeke T, de Vemejoul MC. PTH/PTHrP receptor mRNA is down-regulated in epiphysial cartilage growth plate in uremic rats. Nephrol. Dial. Transplant. 1996; 11: 2008-16.
13. Hruska K. New concept in renal osteodystrophy. Nephrol. Dial. Transplant. 1998; 13: 2755-60.
14. Gonzares EA, Lund RJ, Martin KJ et al. Treatment of a murine model of high turnover renal osteodystrophy by exogenous BMP-7. Kidney Int. 2002; 61: 1322-31.
15. Iwasaki Y, Yamato H, Takahashi T et al. Renal dysfunction causes suppression of bone turnover in the absence of secondary hyperparahyroidsim, leading to adynaic bone disease [Abstract]. J. Am. Soc. Nephrol. 2002; 13: A578.
16. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Rev. 1999; 20: 345-57.
17. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998; 139: 1329-37.
18. Kazama JJ, Shigematsu T, Tsuda E et al. Increased circulating levels of osteoclastogenesis inhibitory factor/osteoprotegerin in patients with chronic renal failure: possible roles in skeletal resistance to PTH in uremia. Am. J. Kidney Dis. 2002; 39: 525-32.
19. Sato T, Tominaga Y, Iwasaki Y et al. Osteopritegerin levels before and after renal transplantation. Am. J. Kidney Dis. 2001; 38 (Suppl. 1): S175-7.
20. Kazama JJ, Kato H, Sato T et al. Circulating osteoprotegerin is not removed through haemodialysis membrane [letter]. Nephrol. Dial. Transplant. 2002; 17: 1860-1.
21. Kazama JJ, Fukagawa M, Shigematsu T et al. Increased circulating osteoprotegerin modifies bone metabolism in uremic patients [Abstract]. J. Am. Soc. Nephrol. 2000; 11: A565.
22. Cohen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol. Dial. Transplant. 2002; 17: 233-8.
23. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am. J. Kidney Dis. 2002; 39: 580-6.